| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
| ln Vitro |
TMPA (5, 10, 20, 40, 80 μM; 6 hours or 10 μM; 0.5, 1, 3, 6, 12, 24, 36, 48 hours) antagonizes Nur77-LKB1 ligated TMPA ( 10 μM; 6 hours) improves the LKB1-AMPKα response but lowers the LKB1-Nur77 response in Lo2 cells under physiological conditions [1]. TMPA directly interacts with LBD with a specific structural picture [1]. TMPA (10, 20 μM; 6 h) promotes LKB1 nuclear export and activates AMPKα in Lo2 cells [1]. TMPA (10, 50, 100 μM; 4 h) damages human T cells RICD (restimulation-induced [1].
|
|---|---|
| ln Vivo |
In individuals with type II diabetes, TMPA (50 mg/kg; intraperitoneal injection; single dose daily for 19 days) can lower blood pressure and enhance diabetic tolerance [1].
|
| Cell Assay |
Cell viability assay [2]
Cell Types: T cell Tested Concentrations: 10, 50, 100 μM Incubation Duration: 4 h Experimental Results: Dramatically diminished T cell RICD (cell death) in a dose-dependent manner [2]. Western Blot Analysis[1] Cell Types: Liver LO2 Cells Tested Concentrations: 10, 20 µM Incubation Duration: 6 hrs (hours) Experimental Results: Experimental Results: Increased LKB1 Ser428 phosphorylation. Western Blot Analysis[1] Cell Types: Liver LO2 cells Tested Concentrations: 5, 10, 20, 40, 80 µM Incubation Duration: 6 hrs (hours) Experimental Results: AmPKα phosphorylation increased in a dose- and time-dependent manner. At a concentration of 10 µM, the LKB1-AmPKα interaction is rescued by reducing the nur77-lKb1 interaction. |
| Animal Protocol |
Animal/Disease Models: Male C57BL/KsJ-Leprdb/Leprdb (db/db ) mice (10 weeks old; type II diabetes model) [1].
Doses: 50 mg/kg Route of Administration: intraperitoneal (ip) injection; daily for 19 days. Experimental Results: Blood glucose diminished Dramatically on day 7 and persisted for the remainder of the test. Increases the amount of phosphorylated AMPKα in mouse liver. |
| References | |
| Additional Infomation |
Ethyl (2,3,4-trimethoxy-6-octanoylphenyl)acetate is an aromatic ketone.
|
| Molecular Formula |
C21H32O6
|
|---|---|
| Molecular Weight |
380.4752
|
| Exact Mass |
380.219
|
| CAS # |
1258275-73-8
|
| Related CAS # |
1258275-73-8
|
| PubChem CID |
60146245
|
| Appearance |
Light yellow to yellow solid
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
480.0±45.0 °C at 760 mmHg
|
| Flash Point |
205.8±28.8 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.491
|
| LogP |
5.25
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
27
|
| Complexity |
438
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1=C([H])C(=C(C(=C1C([H])([H])C(=O)OC([H])([H])C([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H]
|
| InChi Key |
WCYMJQXRLIDSAQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H32O6/c1-6-8-9-10-11-12-17(22)15-13-18(24-3)21(26-5)20(25-4)16(15)14-19(23)27-7-2/h13H,6-12,14H2,1-5H3
|
| Chemical Name |
ethyl 2-(2,3,4-trimethoxy-6-octanoylphenyl)acetate
|
| Synonyms |
TMPA
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 100 mg/mL (262.8 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.57 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.57 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6283 mL | 13.1413 mL | 26.2826 mL | |
| 5 mM | 0.5257 mL | 2.6283 mL | 5.2565 mL | |
| 10 mM | 0.2628 mL | 1.3141 mL | 2.6283 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
